Use of rFVIIa in the trauma setting - Practice patterns in United States trauma centers

John D. Horton, Kent J. Dezee, Michel Wagner

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

Much excitement has been generated regarding the off label use of recombinant factor VIIa (rFVIIa) in the severely injured trauma patient. The purpose of our study is 3-fold: 1) describe the type of centers that use rFVIIa, 2) determine which centers use the drug more frequently, and finally 3) investigate how this drug is being administered at trauma centers. A survey was mailed or e-mailed to 435 trauma centers (Level I and II) throughout the nation. One hundred fifty-six surveys were returned. American College of Surgeons (ACS) verification and trauma Level I designation were independent predictors of rFVIIa use (odds ratio [OR] 3.74 and 5.40, P < 0.05). High users of rFVIIa were defined as those centers that had above median usage of the drug. Level I centers accounted for 67 per cent of the high users. Only the number of fellowship-trained trauma surgeons and trauma volume predicted high usage of rFVIIa (OR 1.38 and 14.09, P < 0.05). Trauma volume predicted whether or not Factor VII users implemented a protocol based approach to administration of the drug (OR 6.57, P < 0.05). Most protocols incorporated packed red blood cells (74%) before giving rFVIIa. The dose of 90 mcg/kg was exceeded in 34 per cent of centers, and 3 per cent used the 200 mcg/kg dose. High volume Level I trauma centers use rFVIIa more frequently and are more likely to use a systematic approach to its administration. However, there is no standardized approach to rFVIIa administration in United States trauma centers.

Original languageEnglish (US)
Pages (from-to)413-417
Number of pages5
JournalAmerican Surgeon
Volume74
Issue number5
StatePublished - May 1 2008

Fingerprint

Trauma Centers
Wounds and Injuries
Odds Ratio
Pharmaceutical Preparations
Off-Label Use
Factor VII
recombinant FVIIa
Erythrocytes

ASJC Scopus subject areas

  • Surgery

Cite this

Horton, J. D., Dezee, K. J., & Wagner, M. (2008). Use of rFVIIa in the trauma setting - Practice patterns in United States trauma centers. American Surgeon, 74(5), 413-417.

Use of rFVIIa in the trauma setting - Practice patterns in United States trauma centers. / Horton, John D.; Dezee, Kent J.; Wagner, Michel.

In: American Surgeon, Vol. 74, No. 5, 01.05.2008, p. 413-417.

Research output: Contribution to journalArticle

Horton, JD, Dezee, KJ & Wagner, M 2008, 'Use of rFVIIa in the trauma setting - Practice patterns in United States trauma centers', American Surgeon, vol. 74, no. 5, pp. 413-417.
Horton, John D. ; Dezee, Kent J. ; Wagner, Michel. / Use of rFVIIa in the trauma setting - Practice patterns in United States trauma centers. In: American Surgeon. 2008 ; Vol. 74, No. 5. pp. 413-417.
@article{0573eb0ad9b04eb3a3f55a9468eab576,
title = "Use of rFVIIa in the trauma setting - Practice patterns in United States trauma centers",
abstract = "Much excitement has been generated regarding the off label use of recombinant factor VIIa (rFVIIa) in the severely injured trauma patient. The purpose of our study is 3-fold: 1) describe the type of centers that use rFVIIa, 2) determine which centers use the drug more frequently, and finally 3) investigate how this drug is being administered at trauma centers. A survey was mailed or e-mailed to 435 trauma centers (Level I and II) throughout the nation. One hundred fifty-six surveys were returned. American College of Surgeons (ACS) verification and trauma Level I designation were independent predictors of rFVIIa use (odds ratio [OR] 3.74 and 5.40, P < 0.05). High users of rFVIIa were defined as those centers that had above median usage of the drug. Level I centers accounted for 67 per cent of the high users. Only the number of fellowship-trained trauma surgeons and trauma volume predicted high usage of rFVIIa (OR 1.38 and 14.09, P < 0.05). Trauma volume predicted whether or not Factor VII users implemented a protocol based approach to administration of the drug (OR 6.57, P < 0.05). Most protocols incorporated packed red blood cells (74{\%}) before giving rFVIIa. The dose of 90 mcg/kg was exceeded in 34 per cent of centers, and 3 per cent used the 200 mcg/kg dose. High volume Level I trauma centers use rFVIIa more frequently and are more likely to use a systematic approach to its administration. However, there is no standardized approach to rFVIIa administration in United States trauma centers.",
author = "Horton, {John D.} and Dezee, {Kent J.} and Michel Wagner",
year = "2008",
month = "5",
day = "1",
language = "English (US)",
volume = "74",
pages = "413--417",
journal = "The American surgeon",
issn = "0003-1348",
publisher = "Southeastern Surgical Congress",
number = "5",

}

TY - JOUR

T1 - Use of rFVIIa in the trauma setting - Practice patterns in United States trauma centers

AU - Horton, John D.

AU - Dezee, Kent J.

AU - Wagner, Michel

PY - 2008/5/1

Y1 - 2008/5/1

N2 - Much excitement has been generated regarding the off label use of recombinant factor VIIa (rFVIIa) in the severely injured trauma patient. The purpose of our study is 3-fold: 1) describe the type of centers that use rFVIIa, 2) determine which centers use the drug more frequently, and finally 3) investigate how this drug is being administered at trauma centers. A survey was mailed or e-mailed to 435 trauma centers (Level I and II) throughout the nation. One hundred fifty-six surveys were returned. American College of Surgeons (ACS) verification and trauma Level I designation were independent predictors of rFVIIa use (odds ratio [OR] 3.74 and 5.40, P < 0.05). High users of rFVIIa were defined as those centers that had above median usage of the drug. Level I centers accounted for 67 per cent of the high users. Only the number of fellowship-trained trauma surgeons and trauma volume predicted high usage of rFVIIa (OR 1.38 and 14.09, P < 0.05). Trauma volume predicted whether or not Factor VII users implemented a protocol based approach to administration of the drug (OR 6.57, P < 0.05). Most protocols incorporated packed red blood cells (74%) before giving rFVIIa. The dose of 90 mcg/kg was exceeded in 34 per cent of centers, and 3 per cent used the 200 mcg/kg dose. High volume Level I trauma centers use rFVIIa more frequently and are more likely to use a systematic approach to its administration. However, there is no standardized approach to rFVIIa administration in United States trauma centers.

AB - Much excitement has been generated regarding the off label use of recombinant factor VIIa (rFVIIa) in the severely injured trauma patient. The purpose of our study is 3-fold: 1) describe the type of centers that use rFVIIa, 2) determine which centers use the drug more frequently, and finally 3) investigate how this drug is being administered at trauma centers. A survey was mailed or e-mailed to 435 trauma centers (Level I and II) throughout the nation. One hundred fifty-six surveys were returned. American College of Surgeons (ACS) verification and trauma Level I designation were independent predictors of rFVIIa use (odds ratio [OR] 3.74 and 5.40, P < 0.05). High users of rFVIIa were defined as those centers that had above median usage of the drug. Level I centers accounted for 67 per cent of the high users. Only the number of fellowship-trained trauma surgeons and trauma volume predicted high usage of rFVIIa (OR 1.38 and 14.09, P < 0.05). Trauma volume predicted whether or not Factor VII users implemented a protocol based approach to administration of the drug (OR 6.57, P < 0.05). Most protocols incorporated packed red blood cells (74%) before giving rFVIIa. The dose of 90 mcg/kg was exceeded in 34 per cent of centers, and 3 per cent used the 200 mcg/kg dose. High volume Level I trauma centers use rFVIIa more frequently and are more likely to use a systematic approach to its administration. However, there is no standardized approach to rFVIIa administration in United States trauma centers.

UR - http://www.scopus.com/inward/record.url?scp=44649112504&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=44649112504&partnerID=8YFLogxK

M3 - Article

C2 - 18481498

AN - SCOPUS:44649112504

VL - 74

SP - 413

EP - 417

JO - The American surgeon

JF - The American surgeon

SN - 0003-1348

IS - 5

ER -